Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 154 of 6351
-
Can a newer drug outperform the standard for chronic myeloid leukemia?
Disease control OngoingThis is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD). This study will be conducted in Chinese patients with newly diagnosed Ph+ Chronic Myelo…
Phase 3 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug shows promise for Hard-to-Treat breast cancer in major trial
Disease control OngoingThis study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: * Cannot be removed by an operation * Has spread to other parts of the body
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy combo shows promise in tough breast cancer
Disease control CompletedThis multicenter, randomized, double-blind study will evaluate the efficacy and safety of Toripalimab (JS001) combined with nab-paclitaxel compared with placebo combined with nab-paclitaxel for first/second line treatment of metastatic or recurrent triple-negative breast cancer (…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells target tough blood cancers in new trial
Disease control OngoingThis is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Ovarian cancer hope: immunotherapy and targeted pill combo tested
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer. The prima…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Immunotherapy combo may keep head and neck cancer at bay
Disease control OngoingThis is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage I…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control CompletedThis study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who receive bridging therapy with talquetamab (Cohort 1b), …
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Hope for early breast cancer: targeted drug may cut recurrence risk
Disease control OngoingA phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Bre…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug cocktail aims to stall liver cancer that Can't be cut out
Disease control OngoingA global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo shows promise against tough stomach cancer
Disease control OngoingZolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called GEJ cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attach…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Chemotherapy-Free combo aims to boost remission in younger AML patients
Disease control CompletedThis study aims to treat non-elderly adult patients, who were previously untreated for acute myeloid leukemia, using venetoclax and azacitidine.
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can High-Dose vitamin c boost chemo against pancreatic cancer?
Disease control CompletedThis clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer). Subjects are randomized between a control group (standard treatment) and an intervention group (pharmacologic ascorbate…
Phase 2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Immunotherapy drug shows promise in keeping lung cancer at bay
Disease control OngoingThis is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have n…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a shot stop asthma before it starts? new trial tests omalizumab in toddlers
Prevention OngoingThis trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflec…
Phase 2 • Sponsor: Boston Children's Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:00 UTC
-
Can targeted radiation boost the power of immunotherapy against melanoma?
Disease control OngoingThe main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofra…
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a modified herpes virus turn the tide against advanced cancer?
Disease control CompletedThis phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma). OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type…
Phase 1/2 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Bladder cancer drug combo shows promise in major trial
Disease control OngoingA Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Immunotherapy after surgery may keep merkel cell cancer at bay
Disease control OngoingThis phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Experimental gene therapy aims to halt rare fatal brain disease in children
Disease control OngoingThis is a phase 1/2, open-label, single dose, dose-escalation clinical trial to evaluate the safety and efficacy of CLN-301 (previous NCH Code: scAAV9.P546.CLN3) delivered intrathecally into the lumbar spinal cord region of subjects with CLN3 Batten disease.
Phase 1/2 • Sponsor: Neela Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells show promise against Hard-to-Treat lymphoma
Disease control CompletedThis is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC